[3]Kang Z, Jin Y, Yu H,et al. Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis. BMC Cancer. 2024 Jun 8;24(1):708. 审批编号：CN-147873 有效期至：2025-11-21本材料...
Various methods used for the detection of HER2 overexpression in cancerous cells including immunohistochemical test, in situ hybridisation techniques and mRNA measures are discussed. Anti HER-2 treatments including monoclonal antibodies such as Trastuzumab and lapatinib; and pertuzumab are also discussed....
Yap YS, Cornelio GH, Devi BC, et al. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer. 2012;107(7):1075-1082. Renfrow JJ, Lesser GJ. Molecular subtyping of brain metastases and implications for therapy. Curr Tr...
Health care professionals discuss the evolving landscape of HER2+ breast cancer treatments, delving into the complexities of the HER2CLIMB trial and strategies for third- and fourth-line interventions.
0:08 | Many of the treatments that we use in the first-line setting for patients with metastatic HER2+ positive breast cancer are based off of the data from the CLEOPATRA trial, which was published in the New England Journal of Medicine a number of years ago. It involved using a taxane...
1. Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar. Cell Reports Medcine. VOLUME 5, ISSUE 6, 101575, JUNE 18, 2024. 2. 乳腺癌疫苗的现状与展望. 实用医学杂志. 2022年,38(20),2505-250...
Academictrialsare now crucial in breast cancer, added Criscitiello. "The prognosis of patients withbreastcancerhas dramatically improved thanks to several new available treatments; we might see a reduced interest from industry to further invest in this disease, especially in trials designed with de-...
[3].Cito P, Rinaldi A, Pisconti S, Longo V. Taxane-rechallenge in HER2-positive breast cancer patients who develop an oligo-progression during pertuzumabtrastuzumab maintenance therapy. Ann Oncol 2017;28(suppl 6):vi43. [4].Yamamoto Y, Iwata H, Naruto T, et al. A randomized, open-...
Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28(8):1700-1712. DOI: 10.1093/annonc/mdx308 ...
In the interview, Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more. 3D rendered medically accurate illustration of breast cancer: © SciePro - stock.adobe.com ...